Navigation Links
Novelos Therapeutics Prices $5.5 Million Public Offering
Date:2/13/2013

MADISON, Wis., Feb. 13, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000.  Each unit consists of one share of our common stock, a Class A Warrant with a one-year term to purchase one-half of a share of our common stock at an exercise price of $0.50 per share and a Class B Warrant with a five-year term to purchase one share of our common stock at an exercise price of $0.50 per share.  Novelos expects to close the transaction, subject to customary conditions, on or about February 19, 2013.

Burrill Securities LLC is acting as a placement agent in a co-lead capacity for the offering.  Dawson James Securities, Inc. is acting as a sub-agent in a co-lead capacity.

The Benchmark Company, LLC is acting as a sub-agent.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction or to any person in any particular jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Burrill Securities LLC, Prospectus Department, One Embarcadero Center, Suite 2700, San Francisco, CA 94111, 415-591-5400 or email: ksheinerman@b-c.com.  Before any investment, an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference therein, for more complete information about Novelos and this offering.

INVESTOR CONT
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
2. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
3. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
4. Novelos Therapeutics Closes $2 Million Private Placement
5. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... N.J. , May 6, 2015  IGI Laboratories, Inc. ... specialty generic pharmaceutical company, will be presenting today at the ... take place on May 6 th and 7 th ... Jason Grenfell-Gardner , CEO and President ... Laboratories, Inc., will present today, May 6, 2015, at 3:30 p.m. ET. ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... urges psoriasis patients to take control,of their health, help ... A study released,this week showing that people with ... should prompt them to take steps to improve their,overall ... study -- published in the Archives of Dermatology and ...
... Holdings, Inc. (OTC Bulletin Board: LIXT) a developer ... cancer, announced the,closing of a private placement. In ... Stock at a price of $0.65 per share ... acted as placement agent and,received $65,000 in commissions ...
Cached Medicine Technology:Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 2Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 3Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement 2Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement 3
(Date:5/6/2015)... May 06, 2015 Aging2.0 ... today announced the latest lineup of speakers and sponsors ... The invitation-only event, scheduled for May 18-19 in San ... executives, consumer technology leaders, investors and more than 50 ... cultivate partnerships and discover new products and services for ...
(Date:5/6/2015)... 06, 2015 Hope For The Warriors® ... Casino Night at the New York Athletic Club on ... Hope For The Warriors®, a national nonprofit dedicated to ... and restoring hope for our service members and our ... to support local and nationwide military families. The Barry ...
(Date:5/6/2015)... Novodiax announced today that they will ... with Ed Begley Jr., airing via Discovery Channel ... , This segment will explore Novodiax, a company ... will learn about Novodiax’s polymer detection system-based Direct ... scenes to investigate how, based on this technology, ...
(Date:5/6/2015)... When it comes to advice concerning health ... respected than those of a physician. It is thus ... more weight than those who received no such trustworthy ... University of Georgia and published in the March edition ... advised by their physicians dropped more pounds, on average, ...
(Date:5/6/2015)... 06, 2015 Healthcare marketing agency ... a silver award in the 2015 Aster Awards for ... and Ellis Medicine’s maternity campaign, respectively. The Aster Awards ... organizations and marketing agencies. , The branding campaign ... line — other/misc. category and hospital 150-200 bed group. ...
Breaking Medicine News(10 mins):Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:4th Annual Casino Night Draws Support for Military Families in New York City Region 2Health News:Novodiax to Be Featured in Upcoming Episode of Innovations TV Series 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 3Health News:Smith & Jones Wins in 2015 Aster Awards for Healthcare Marketing 2
... enabled its Contract Sales Management and Outsourced Sales Services capabilities with ... ... Boston, MA (PRWEB) August 31, 2008 -- SCiSOURCE, an international provider ... addition of Joseph P. Connell to its Management Team. This announcement ...
... life of retinal cells that fight age-related macular ... Eating plenty of antioxidant-rich food such as blueberries, ... degeneration, the leading cause of age-related blindness in ... , U.S. researchers found that antioxidants disrupt a ...
... Aflac Incorporated,(NYSE: AFL ) announced today that it ... Tokyo, Japan. Members of Aflac Japan,s management and,its sales ... meeting,agenda follows:, September 7, 2008, 8:00 p.m. ... 2008, 9:00 a.m. - 3:30 p.m. Tokyo time) ...
... Conseco Insurance Company, a life,and health insurance company, ... life insurance product, ConsecoLifeOptions. The policy,provides upside potential ... universal life policy that offers the,opportunity for long-term ... 1%. Clients can customize their coverage levels with ...
... to address the issue, DENVER, Aug. 29 ... Former President Bill Clinton called,for a reinvigorated response ... In praising Presidential nominee Barack Obama, Clinton said,"He ... leadership in,an area in which I am deeply ...
... raises odds for malignancy, study finds , , FRIDAY, Aug. ... World War II atomic bomb blasts in Hiroshima and ... the onset of a form of thyroid cancer, new ... linked to a particular genetic mutation involving the so-called ...
Cached Medicine News:Health News:SCiSOURCE LLC Makes Key Addition to its Management Team 2Health News:Antioxidant-Rich Diet May Protect Against Eye Disease 2Health News:Aflac Incorporated to Webcast Tokyo Analysts Meeting 2Health News:Aflac Incorporated to Webcast Tokyo Analysts Meeting 3Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: